Overall, our findings clearly support the use of a NMIBC prognosis prediction model, based on GAS5 expression and the independent clinicalpathologic prognostic markers of NMIBC, namely tumour stage, tumour grade and EORTC-risk stratification, using biopsy specimens of TURBT-treated TaT1 patients. The gene discussed is GAS5; the disease is neoplasm.